Lonidamine
Lonidamine structure
|
Common Name | Lonidamine | ||
|---|---|---|---|---|
| CAS Number | 50264-69-2 | Molecular Weight | 321.158 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 537.9±45.0 °C at 760 mmHg | |
| Molecular Formula | C15H10Cl2N2O2 | Melting Point | 207-209°C | |
| MSDS | Chinese USA | Flash Point | 279.1±28.7 °C | |
| Symbol |
GHS07, GHS08 |
Signal Word | Danger | |
|
A novel effect of DMOG on cell metabolism: direct inhibition of mitochondrial function precedes HIF target gene expression.
Biochim. Biophys. Acta 1847 , 1254-66, (2015) Abnormal accumulation of oncometabolite fumarate and succinate is associated with inhibition of mitochondrial function and carcinogenesis. By competing with α-ketoglutarate, oncometabolites also activate hypoxia inducible factors (HIFs), which makes oncometab... |
|
|
Aerobic glycolysis tunes YAP/TAZ transcriptional activity.
EMBO J. 34 , 1349-70, (2015) Increased glucose metabolism and reprogramming toward aerobic glycolysis are a hallmark of cancer cells, meeting their metabolic needs for sustained cell proliferation. Metabolic reprogramming is usually considered as a downstream consequence of tumor develop... |
|
|
Male contraception: history and development.
Urol. Clin. North Am. 41(1) , 145-61, (2014) Although the twentieth century has seen great strides in the development of female contraception, not a single new agent has been introduced as an approved method for common use for male contraception. Condoms (considered uncomfortable by some) and vasectomy ... |
|
|
Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids.
Oncol. Rep. 34 , 1533-42, (2015) There is a strong rationale for targeting the metabolic alterations of cancer cells. The most studied of these are the higher rates of glycolysis, glutaminolysis and de novo synthesis of fatty acids (FAs). Despite the availability of pharmacological inhibitor... |
|
|
Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics.
Proc. Natl. Acad. Sci. U. S. A. 109(40) , 16288-93, (2012) Mitochondrial dysfunctions cause numerous human disorders. A platform technology based on biodegradable polymers for carrying bioactive molecules to the mitochondrial matrix could be of enormous potential benefit in treating mitochondrial diseases. Here we re... |
|
|
Modulation of cellular radiation responses by 2-deoxy-D-glucose and other glycolytic inhibitors: implications for cancer therapy.
J. Cancer Res. Ther. 5 , S57-60, (2009) 2-Deoxy-D-glucose (2-DG), a glycolytic inhibitor, was observed earlier to increase DNA, chromosomal, and cellular damage in tumor cells, by inhibiting energy-dependent repair processes. Lonidamine (LND) selectively inhibits glycolysis in cancer cells. It dama... |
|
|
The 18-kDa translocator protein (TSPO) disrupts mammary epithelial morphogenesis and promotes breast cancer cell migration.
PLoS ONE 8 , e71258, (2013) Mitochondria play important roles in cancer progression and have emerged as viable targets for cancer therapy. Increasing levels of the outer mitochondrial membrane protein, 18-kDa translocator protein (TSPO), are associated with advancing breast cancer stage... |
|
|
Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells.
J. Transl. Med. 7 , 13, (2009) High grade gliomas are one of the most difficult cancers to treat and despite surgery, radiotherapy and temozolomide-based chemotherapy, the prognosis of glioma patients is poor. Resistance to temozolomide is the major barrier to effective therapy. Alternativ... |
|
|
Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation.
Biochem. Pharmacol. 82(11) , 1619-29, (2011) Lonidamine is a safe, clinically useful anti-tumor drug, but its efficacy is generally low when used in monotherapy. We here demonstrate that lonidamine efficaciously cooperates with the anti-leukemic agent arsenic trioxide (ATO, Trisenox) to induce apoptosis... |
|
|
Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer.
Nanomedicine: Nanotechnology, Biology, and Medicine 7(4) , 435-44, (2011) The aim of this study was to assess the biodistribution and pharmacokinetics of epidermal growth factor receptor (EGFR)-targeted polymer-blend nanoparticles loaded with the anticancer drugs lonidamine and paclitaxel. Plasma, tumor, and tissue distribution pro... |